Cargando…
Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Behçet’s disease
BACKGROUND: Ocular symptoms in Behçet’s disease (BD) begin mostly before 30 years of age according to international surveys, and BD activity may decrease with age. Information regarding the treatment of ocular symptoms in elderly BD patients is thus scant. Anti-TNFα antibody has recently demonstrate...
Autores principales: | Karube, Hisako, Kamoi, Koju, Ohno-Matsui, Kyoko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045905/ https://www.ncbi.nlm.nih.gov/pubmed/27729816 http://dx.doi.org/10.2147/IMCRJ.S117731 |
Ejemplares similares
-
A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet’s syndrome
por: Horiguchi, Noe, et al.
Publicado: (2020) -
Safety of intraocular anti-VEGF antibody treatment under in vitro HTLV-1 infection
por: Zong, Yuan, et al.
Publicado: (2023) -
Mechanism of Secondary Glaucoma Development in HTLV-1 Uveitis
por: Zong, Yuan, et al.
Publicado: (2022) -
Safety of Infliximab for the Eye Under Human T-Cell Leukemia Virus Type 1 Infectious Conditions in vitro
por: Uchida, Minami, et al.
Publicado: (2019) -
In vitro Evaluation of the Safety of Adalimumab for the Eye Under HTLV-1 Infection Status: A Preliminary Study
por: Kurozumi-Karube, Hisako, et al.
Publicado: (2020)